KRYSTAL BIOTECH INC (NASDAQ:KRYS) Q2 2025 Earnings Beat Estimates as VYJUVEK Drives Strong Revenue Growth
By Mill Chart
Last update: Aug 4, 2025
KRYSTAL BIOTECH INC (NASDAQ:KRYS) reported second-quarter 2025 financial results, with revenue and earnings per share (EPS) surpassing analyst expectations. The company’s performance, particularly in its flagship product VYJUVEK, drove the beat, while the market reaction reflects optimism as shares rose nearly 4% in pre-market trading.
Earnings and Revenue Highlights
- Revenue: Reported at $96.04 million, exceeding the consensus estimate of $93.8 million. This marks a continuation of strong commercial execution, with cumulative VYJUVEK revenue reaching $525.4 million since its launch in Q3 2023.
- EPS: Came in at $1.29, beating the estimated $1.16, indicating improved profitability and operational efficiency.
The outperformance suggests robust demand for VYJUVEK, a gene therapy treatment for dystrophic epidermolysis bullosa (DEB), which recently gained approval in Japan for use in patients from birth.
Market Reaction
The positive earnings surprise appears to have bolstered investor confidence:
- Pre-market trading: Shares were up ~4%, signaling a favorable reaction to the earnings beat.
- Recent performance: The stock has shown steady gains over the past month (~9.7%), reflecting broader market optimism around the company’s growth trajectory.
Press Release Summary
Key takeaways from Krystal Biotech’s Q2 2025 update include:
- VYJUVEK’s continued commercial success, with $96 million in Q2 revenue.
- Regulatory expansion in Japan, broadening the drug’s addressable market.
- No explicit forward guidance was provided, but analyst estimates for Q3 2025 project revenue of $103.85 million and EPS of $1.32, suggesting expectations of sustained growth.
Looking Ahead
Analysts forecast full-year 2025 revenue at $407 million, with Q3 estimates aligning with sequential growth. The lack of company-provided outlook does not appear to have dampened sentiment, as the market seems to be pricing in continued execution on VYJUVEK’s global rollout.
For more detailed earnings estimates and historical performance, see Krystal Biotech’s earnings data.
Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.
